Conotoxin fusion protein MGS-AFP3 (R509Y) as well as preparation method and application thereof
By connecting the conotoxin MGS gene to AFP3 (R509Y) gene and transfecting conotoxin cells, the efficient expression and purification of the conotoxin fusion protein MGS-AFP3 (R509Y) was achieved, and the failure to obtain it effectively in the prior art was solved. The problem of this protein significantly inhibits the growth of lung cancer cells and provides an effective tool for lung cancer treatment research.
Patent Information
- Application Number
- CN202411058468.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
The existing technology has failed to effectively use conopocrine cells to obtain the conopocrine toxin fusion protein MGS-AFP3 (R509Y), which has the potential to inhibit the growth of lung liver adenocarcinoma cells, and no relevant reports have described its expression method.
By ligating the conotoxin MGS gene with the AFP3 (R509Y) gene, inserting the expression vector and transfecting the conotoxin cells, and undergoing suspension culture at 37°C. The highly efficiently expressed conotoxin fusion protein MGS-AFP3 (R509Y) was subsequently obtained by concentration and purification. ).
The efficient expression and purification of the conotoxin fusion protein MGS-AFP3 (R509Y) was achieved, which significantly inhibited the growth of lung cancer cells, especially lung cancer cells that overexpressed alpha-fetoprotein, and provided an effective tool for lung cancer treatment research.
Smart Images

Figure CN118978603A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, relates to genetic engineering and protein engineering, and in particular to a conus toxin fusion protein MGS-AFP3 (R509Y) obtained through conus cells, and a preparation method and application thereof. Background Art
[0002] Hepatic adenocarcinoma of the lung (HAL) is a rare cancer. The expression of alpha-fetoprotein and nicotinic acetylcholine receptors in patients promotes cancer development. The applicant's research found that the conotoxin MGS can inhibit the activity of nicotinic acetylcholine receptors. And AFP3 (R509Y) (a mutant of the third domain of alpha-fetoprotein) can competitively inhibit the activity of alpha-fetoprotein. In order to design anticancer drugs for the treatment of HAL, the conotoxin MGS is fused with AFP3 (R509Y) for expression. This conotoxin fusion protein MGS-AFP3 (R509Y) can simultaneously inhibit the activity of nicotinic acetylcholine receptors and alpha-fetoprotein. The applicant's research data show that the fusion protein MGS-AFP3 (R509Y) can be highly expressed in conus cells. The fusion protein MGS-AFP3 (R509Y) can inhibit the growth of lung cancer cells, especially the growth of lung cancer cells that overexpress alpha-fetoprotein.
[0003] At present, there is no report on the method of obtaining conotoxin fusion protein MGS-AFP3 (R509Y) using cono cells. Summary of the invention
[0004] The purpose of the present invention is to provide a conotoxin fusion protein MGS-AFP3 (R509Y) and a method for efficiently expressing the conotoxin fusion protein MGS-AFP3 (R509Y) using cono cells. The protein expressed by the method has good activity and can be used for research on lung cancer treatment.
[0005] In order to achieve the above object, the technical scheme of the present invention is: to provide a method for efficiently expressing the conus toxin fusion protein MGS-AFP3 (R509Y), specifically, the conus cells extracted from conus such as Conus spp. and Conus harvestii are cultured in suspension in a carbon dioxide incubator at 37°C.
[0006] The invention connects the conotoxin MGS gene and the AFP3 (the third structural domain of human alpha-fetoprotein) gene mutant (R509Y), inserts the connected conotoxin fusion protein MGS-AFP3 (R509Y) gene into an expression vector, then transfects cono cells with the constructed vector to promote the cono cells to efficiently secrete and express the conotoxin fusion protein into a culture medium, and then obtains the conotoxin fusion protein MGS-AFP3 (R509Y) by concentrating and purifying the culture medium.
[0007] Furthermore, the method for efficiently expressing the conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein of the present invention specifically comprises the following steps:
[0008] (1) Construction of expression vector
[0009] The conotoxin MGS gene (atgggctgct gccccaaccc cagctgcagg cagaaccaccccgagctgtg cagcaaccag) and the AFP3 mutant (R509Y) gene (Gen Bank: the third domain of NM_001134, AFP residues 401 to 610, wherein 509R is mutated to Y) are connected, and 6 histidine sequences are added to the C-terminus. The specific synthetic gene sequences are shown in SEQ ID NO: 1 and SEQ ID NO: 2 in the sequence table. The synthesized gene is inserted into the expression vector PTT5 to obtain the PTT5-MGS-AFP3 (R509Y) plasmid;
[0010] (2) Expression of conotoxin fusion protein MGS-AFP3 (R509Y) in conotoxin cells
[0011] The PTT5-MGS-AFP3 (R509Y) plasmid was transfected into cone snail cells, and after suspension culture at 37° C. in a carbon dioxide incubator for 96 hours, the cone snail cells secreted the conotoxin fusion protein MGS-AFP3 (R509Y) into the culture medium, and the culture medium was collected to obtain a culture medium containing the protein.
[0012] (3) Purification of conotoxin fusion protein MGS-AFP3 (R509Y)
[0013] The culture medium collected in step (2) is added to HBS (10 mM Hepes, pH 7.2, 150 mM NaCl) solution and concentrated by ultrafiltration membrane. The concentrate is passed through a nickel column and then eluted with an eluent. The eluent is purified by gel chromatography to obtain the MGS-AFP3 (R509Y) fusion protein.
[0014] Furthermore, the protein molecular weight of the MGS-AFP3 (R509Y) fusion protein obtained by the present invention is 20-30KD (molecular weight when denatured). When active, dimers will appear, so the active protein will show two bands in the Coomassie brilliant blue staining of SDS / PAGE gel, one band is 20-30KD and the other band is 40-60KD.
[0015] The invention also provides application of conotoxin fusion protein MGS-AFP3 (R509Y) in inhibiting the activity of lung cancer cells.
[0016] The MTT method was used to detect the effect of conotoxin fusion protein MGS-AFP3 (R509Y) on the growth of lung cancer cells A549: Conotoxin fusion protein MGS-AFP3 (R509Y) had a certain inhibitory effect on the growth of A549 cells; after the lung cancer cells A549 were treated with conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, the growth activity of the cells decreased to about 80%.
[0017] In addition, the conotoxin fusion protein MGS-AFP3 (R509Y) can inhibit the growth of A549 cells expressing AFP. After transfecting the A549 cells with the pc3.1AFP vector, A549 cells expressing AFP (AFP-A549 cells) were obtained. After the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL was applied to AFP-A549 cells for 48 hours, the growth activity of the cells decreased to about 70%.
[0018] It can also be observed under the microscope that the conotoxin fusion protein MGS-AFP3 (R509Y) can inhibit the growth of A549 cells. After the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL was applied to A549 cells for 48 hours, more cells died.
[0019] Under electron microscope, A549 cells in normal culture and A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) were observed. The A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) showed cell membrane dissolution and damage.
[0020] Flow cytometry was used to detect A549 cells under normal culture and A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y). A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) showed more apoptosis.
[0021] Beneficial effects of the present invention:
[0022] The conotoxin fusion protein MGS-AFP3 (R509Y) obtained from the cono cells obtained by the invention has good activity and high purity. The protein expressed by the method can be applied to the treatment research of lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1: Agarose electrophoresis of the conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein expression vector. Lane 1: Marker; Lane 2: Conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein expression vector; Lane 3: Conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein expression vector was double-digested with EcoR I and BamH I for verification.
[0024] Figure 2 : SDS-PAGE electrophoresis of conotoxin fusion protein MGS-AFP3 (R509Y). Lane 1: denatured conotoxin fusion protein MGS-AFP3 (R509Y); Lane 2: non-denatured conotoxin fusion protein MGS-AFP3 (R509Y); Lane 3: Marker.
[0025] Figure 3 :MTT method was used to detect the effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549.
[0026] Figure 4 :The effect of conotoxin fusion protein MGS-AFP3(R509Y) expressed by Conus truncatus cells on the growth of lung cancer cells A549 was observed under a microscope. Figure 4 A shows the growth of A549 cells under normal culture; Figure 4 B is that after A549 cells were treated with conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, a relatively large number of cells died.
[0027] Figure 5 :The effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549 was observed under electron microscope. Figure 5 A is the growth of A549 cells under normal culture; Figure 5 B is the growth of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y).
[0028] Figure 6 :Flow cytometry was used to detect the effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549. Figure 6 A is the growth of A549 cells under normal culture; Figure 6 B is the growth of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y).
[0029] Figure 7: SDS-PAGE electrophoresis of the conotoxin fusion protein MGS-AFP3 (R509Y) expressed in conus cells. Lane 1: Marker; Lane 2: Non-denatured conotoxin fusion protein MGS-AFP3 (R509Y); Lane 3: Denatured conotoxin fusion protein MGS-AFP3 (R509Y).
[0030] Figure 8 :MTT method was used to detect the effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549.
[0031] Fig. 9 :The effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549 was observed under a microscope. Fig. 9 A shows the growth of A549 cells under normal culture; Fig. 9 B is that after A549 cells were treated with conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, a relatively large number of cells died.
[0032] Fig.10 :The effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549 was observed under electron microscope. Fig.10 A is the growth of A549 cells under normal culture; Fig.10 B is the growth of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y).
[0033] Fig.11 :Flow cytometry was used to detect the effect of conotoxin fusion protein MGS-AFP3(R509Y) on the growth of lung cancer cells A549. Fig.11 A is the growth of A549 cells under normal culture; Fig.11 B is the growth of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y). DETAILED DESCRIPTION
[0034] Example 1 Method for using the conus toxin fusion protein MGS-AFP3 (R509Y) expressed by Conus spp. 1. Crush the shell of living Conus spp. cells, remove the soft tissue of Conus spp., cut the tissue into small pieces, and then crush it with a blender, and add trypsin for digestion. Then centrifuge and transfer the cells obtained by centrifugation into a cell bottle for suspension culture at 37°C.
[0035] 2. Connect the conotoxin MGS gene and the AFP3 mutant (R509Y) gene (Gen Bank: NM_001134, the third domain, AFP residues 401 to 610, where 509R is mutated to Y), and add 6 histidine sequences to the C-terminus. The specific synthetic gene sequence is shown in SEQ ID NO: 1 in the sequence table. Insert the synthesized gene into the expression vector PTT5 to obtain the PTT5-MGS-AFP3 (R509Y) plasmid;
[0036] For specific results, see Figure 1 , Figure 1 This is the agarose electrophoresis diagram of the conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein expression vector. Lane 1: Marker; Lane 2: Conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein expression vector; Lane 3: Conotoxin fusion protein MGS-AFP3 (R509Y) fusion protein expression vector was double-digested with EcoRI and BamH I to verify that the fragment of MGS-AFP3 (R509Y) size was displayed at 780 bp, indicating that the connection was correct.
[0037] 3. Expression of Conotoxin Fusion Protein MGS-AFP3(R509Y) in Cono cells
[0038] The PTT5-MGS-AFP3 (R509Y) plasmid was transfected into the Conus conus cells, and after suspension culture at 37° C. in a carbon dioxide incubator for 96 hours, the Conus conus cells secreted the conus toxin fusion protein MGS-AFP3 (R509Y) into the culture medium, and the culture medium was collected to obtain a culture medium containing the protein.
[0039] 4. Purification of Conotoxin Fusion Protein MGS-AFP3(R509Y)
[0040] The culture medium collected above was added to HBS (10 mM Hepes, pH 7.2, 150 mM NaCl) solution and concentrated by ultrafiltration membrane. The concentrate was passed through a nickel column and then eluted with an eluent. The eluent was purified by gel chromatography to obtain the MGS-AFP3 (R509Y) fusion protein.
[0041] Results Figure 2 , Figure 2 This is the SDS-PAGE electrophoresis diagram of the conotoxin fusion protein MGS-AFP3 (R509Y) expressed by the Conus spp. Lane 1: denatured conotoxin fusion protein MGS-AFP3 (R509Y); Lane 2: non-denatured conotoxin fusion protein MGS-AFP3 (R509Y); Lane 3: Marker.
[0042] The protein molecular weight of the MGS-AFP3 (R509Y) fusion protein obtained by the present invention is 20-30KD (molecular weight when denatured). When active, dimers will appear, so the active protein will show two bands in the Coomassie brilliant blue staining of SDS / PAGE gel, one band is 20-30KD (monomer) and the other band is 40-60KD (dimer).
[0043] 5. The MTT method was used to detect the effect of conotoxin fusion protein MGS-AFP3 (R509Y) on the growth of lung cancer cells A549: After the A549 lung cancer cells were treated with the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, the growth activity of the cells decreased to about 80%. In addition, the conotoxin fusion protein MGS-AFP3 (R509Y) can inhibit the growth of A549 cells expressing AFP. After transfecting the A549 cell growth cells with the pc3.1AFP vector, A549 cells expressing AFP (AFP-A549 cells) were obtained; after the AFP-A549 cells were treated with the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, the growth activity of the cells decreased to 70%. The specific results are shown in Figure 3 .pass Figure 3 It can be seen that the conotoxin fusion protein MGS-AFP3 (R509Y) has a certain inhibitory effect on the growth of A549 cells and A549 cells expressing AFP.
[0044] 6. It can also be observed under a microscope that the conotoxin fusion protein MGS-AFP3 (R509Y) can inhibit the growth of A549 cells. The results are shown in Figure 4 . Figure 4 A shows the growth of A549 cells under normal culture; Figure 4 B is that after A549 cells were treated with conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, a relatively large number of cells died.
[0045] 7. The effect of conotoxin fusion protein MGS-AFP3 (R509Y) on the growth of lung cancer cells A549 was observed under electron microscope. The specific results are shown in Figure 5 . Figure 5 A is the growth of A549 cells under normal culture; Figure 5 B is the growth condition of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y). Cell membrane of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) was dissolved and damaged.
[0046] 8. Flow cytometry was used to detect the effect of conotoxin fusion protein MGS-AFP3 (R509Y) on the growth of lung cancer cells A549. The specific results are shown in Figure 6 . Figure 6 A is the growth of A549 cells under normal culture; Figure 6 B is the growth of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y). A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) showed a relatively large number of apoptotic cells.
[0047] Example 2 Method for using the conus toxin fusion protein MGS-AFP3 (R509Y) expressed by Conus vesiculosus cells 1. Crush the shells of living Conus vesiculosus cells, remove the soft tissue of the Conus vesiculosus, cut the tissue into small pieces, and then crush it with a blender, and add trypsin for digestion. Then centrifuge and transfer the cells obtained by centrifugation to a cell bottle for suspension culture at 37°C.
[0048] 2. Connect the conotoxin MGS gene and the AFP3 mutant (R509Y) gene (Gen Bank: NM_001134, the third domain, AFP residues 401 to 610, where 509R is mutated to Y), and add 6 histidine sequences to the C-terminus. The specific synthetic gene sequence is shown in SEQ ID NO: 1 in the sequence table. Insert the synthesized gene into the expression vector PTT5 to obtain the PTT5-MGS-AFP3 (R509Y) plasmid (the result is shown in Figure 1 shown);
[0049] 3. Expression of Conus toxin fusion protein MGS-AFP3(R509Y) in Conus harzianus cells
[0050] The PTT5-MGS-AFP3 (R509Y) plasmid was transfected into Conus harveyi cells, and after suspension culture at 37°C in a carbon dioxide incubator for 72 hours, the Conus cells secreted the conus toxin fusion protein MGS-AFP3 (R509Y) into the culture medium, and the culture medium was collected to obtain a culture medium containing the protein.
[0051] 4. Purification of Conotoxin Fusion Protein MGS-AFP3(R509Y)
[0052] The culture medium collected above was added to HBS (10 mM Hepes, pH 7.2, 150 mM NaCl) solution and concentrated by ultrafiltration membrane. The concentrate was passed through a nickel column and then eluted with an eluent. The eluent was purified by gel chromatography to obtain the MGS-AFP3 (R509Y) fusion protein.
[0053] Results Figure 7 , Figure 7 This is the SDS-PAGE electrophoresis of the conotoxin fusion protein MGS-AFP3 (R509Y) expressed by Conus harveyi cells. Lane 1: Marker; Lane 2: Non-denatured conotoxin fusion protein MGS-AFP3 (R509Y); Lane 3: Denatured conotoxin fusion protein MGS-AFP3 (R509Y).
[0054] 5. The MTT method was used to detect the effect of conotoxin fusion protein MGS-AFP3 (R509Y) on the growth of lung cancer cells A549: After the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300μg / mL was applied to A549 lung cancer cells for 48 hours, the cell growth activity decreased to 78%. In addition, the conotoxin fusion protein MGS-AFP3 (R509Y) can inhibit the growth of A549 cells expressing AFP. After transfecting the A549 cell growth cells with the pc3.1AFP vector, A549 cells expressing AFP (AFP-A549 cells) were obtained. After the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300μg / mL was applied to AFP-A549 cells for 48 hours, the cell growth activity decreased to 71%. The specific results are shown in Figure 8 .
[0055] 6. After the A549 cells were treated with the conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, more A549 cells were observed to die under a microscope. The specific results are shown in Figure Fig. 9 .in Fig. 9 A shows the growth of A549 cells under normal culture; Fig. 9 B is that after A549 cells were treated with conotoxin fusion protein MGS-AFP3 (R509Y) at a concentration of 300 μg / mL for 48 hours, a relatively large number of cells died.
[0056] 7. After 48 hours of exposure to the conotoxin fusion protein MGS-AFP3 (R509Y), the A549 cells showed cell membrane dissolution and damage under electron microscopy. The specific results are shown in Fig.10 . Fig.10 A is the growth of A549 cells under normal culture; Fig.10 B is the growth condition of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y). Cell membrane of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) was dissolved and damaged.
[0057] 8. After 48 hours of treatment with conotoxin fusion protein MGS-AFP3 (R509Y), flow cytometry detected a large number of apoptotic cells in A549 cells. The specific results are shown in Fig.11 . Fig.11 A is the growth of A549 cells under normal culture; Fig.11 B is the growth of A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y). A549 cells treated with conotoxin fusion protein MGS-AFP3 (R509Y) showed a relatively large number of apoptotic cells.
[0058] Of course, the above description is not a limitation of the present invention, and the present invention is not limited to the above examples. Any changes, modifications, additions or substitutions made by ordinary technicians in this technical field within the essential scope of the present invention should fall within the protection scope of the present invention.
Claims
1. Application of the conotoxin MGS gene in the preparation of conotoxin fusion protein MGS-AFP3 (R509Y), characterized in that: The conotoxin MGS gene sequence is: atgggctgct gccccaaccc cagctgcagg cagaaccaccccgagctgtg cagcaaccag.
2. A gene encoding a conotoxin fusion protein MGS-AFP3 (R509Y), characterized in that: The gene sequence is shown in SEQ ID NO:
1.
3. A method for synthesizing a gene encoding a conotoxin fusion protein MGS-AFP3 (R509Y), characterized in that: The steps are as follows: connect the conotoxin MGS gene (atgggctgct gccccaaccc cagctgcagg cagaaccacc ccgagctgtgcagcaaccag) and the AFP3 mutant (R509Y) gene (Gen Bank: the third domain of NM_001134, residues 401 to 610, in which 509R is mutated to Y), and add 6 histidine sequences at the C-terminus.
4. An expression vector, characterized in that: Comprising the nucleic acid molecule of claim 2.
5. A method for obtaining conotoxin fusion protein MGS-AFP3 (R509Y) in conus cells, characterized in that: The conotoxin MGS gene and the AFP3 (human alpha-fetoprotein third domain) gene mutant (R108Y) are connected, and the connected conotoxin fusion protein MGS-AFP3 (R108Y) gene is inserted into an expression vector. The constructed vector is then transfected into cono cells to encourage the cono cells to efficiently secrete and express the conotoxin fusion protein into the culture medium. The conotoxin fusion protein MGS-AFP3 (R108Y) is then obtained by concentrating and purifying the culture medium.
6. The method for obtaining conotoxin fusion protein MGS-AFP3 (R108Y) in conus cells as claimed in claim 5, characterized in that: The specific steps include: (1) Construction of expression vector The conotoxin MGS gene (atgggctgct gccccaaccc cagctgcagg cagaaccacc ccgagctgtgcagcaaccag) and the AFP3 mutant (R509Y) gene (Gen Bank: NM_001134, domain 3, residues 401-610, with 509R mutated to Y) were connected, and a 6-histidine sequence was added to the C-terminus; The synthesized gene was inserted into the expression vector PTT5 to obtain the PTT5-MGS-AFP3 (R509Y) plasmid; (2) Expression and purification of conotoxin fusion protein MGS-AFP3 (R509Y) in cono cells PTT5-MGS-AFP3 (R108Y) plasmid was transfected into cono cells and cultured in suspension for 96 h. The culture medium was collected and added to HBS solution and concentrated by ultrafiltration membrane. The concentrate was passed through a nickel column and then eluted with eluent. The eluent was purified by gel chromatography to obtain the MGS-AFP3 (R108Y) fusion protein.
7. Conotoxin fusion protein MGS-AFP3 (R108Y), the amino acid sequence of which is shown in SEQ ID NO:
2.
8. The conotoxin fusion protein MGS-AFP3 (R108Y) prepared according to any one of the above claims, characterized in that: The molecular weight of the protein when denatured is 20-30KD, and when active, dimers will appear. The active protein will show two bands in Coomassie brilliant blue staining of SDS / PAGE gel, one band is 20-30KD, and the other band is 40-60KD.
9. Use of the conotoxin fusion protein MGS-AFP3 (R509Y) prepared according to the above claims in drugs for treating lung cancer.
